Safety and Effectiveness of Two Doses of ABT-874 as Compared to Placebo in Subjects With Multiple Sclerosis (MS)

A 24-Week, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Dose Finding, Safety, Tolerability, and Efficacy Study of the Human Anti-IL-12 Antibody ABT-874 in Subjects With Multiple Sclerosis With a 24-Week Double-Blind, Active Extension Phase

The objective of the trial is to study the safety and effectiveness of ABT-874 administered weekly or every other week in patients with relapsing remitting and secondary progressive multiple sclerosis as compared to placebo. Effectiveness will be measured based on MRI scans done periodically throughout the study.

Study Overview

• Status: Completed
• Conditions: Multiple Sclerosis
• Intervention / Treatment: Drug: Placebo; Drug: ABT-874/Human monoclonal antibody against IL-12

Detailed Description

This study was done in subjects with relapsing remitting MS or secondary progressive MS with the objective of assessing the safety and efficacy of 200 mg of ABT-874 weekly or QOW versus placebo. There were 3 phases to the study, 24 week double blind followed by 24 weeks of an active extension, followed by 48 weeks of double blind active extension. The trial was discontinued by Abbott in Aug 2006.

• Study Type: Interventional
• Enrollment (Actual): 215
• Phase: Phase 2

Contacts and Locations

Study Locations

• Canada
  • Greenfield Park, Canada, J4V 2H1
    • Site Reference ID/Investigator# 132
  • Halifax, Canada, B3H 3A7
    • Site Reference ID/Investigator# 130
  • Ottawa, Canada, K1H 8L6
    • Site Reference ID/Investigator# 82
  • Sherbrooke, Canada, J1H 5N4
    • Site Reference ID/Investigator# 169
  • Vancouver, Canada, V6T 2B5
    • Site Reference ID/Investigator# 134
• Germany
  • Frankfurt, Germany, 60528
    • Site Reference ID/Investigator# 149
• Netherlands
  • Breda, Netherlands, 4818 CK
    • Site Reference ID/Investigator# 137
  • Nieuwegein, Netherlands, 3435 CM
    • Site Reference ID/Investigator# 148
  • Nijmwegen, Netherlands, 6533 PA
    • Site Reference ID/Investigator# 138
  • Sittard, Netherlands, 6131 BK
    • Site Reference ID/Investigator# 139
• United Kingdom
  • Liverpool, United Kingdom, L97LJ
    • Site Reference ID/Investigator# 159
  • London, United Kingdom, SE1 1UL
    • Site Reference ID/Investigator# 140
  • Newcastle upon Tyne, United Kingdom, NE1 4LP
    • Site Reference ID/Investigator# 142
  • Nottingham, United Kingdom, NG7 2UH
    • Site Reference ID/Investigator# 141
  • Oxford, United Kingdom, OX2 6HE
    • Site Reference ID/Investigator# 144
  • Stoke on Trent, United Kingdom, ST4 7LN
    • Site Reference ID/Investigator# 143
  • Whitechapel, United Kingdom, E1 1 BB
    • Site Reference ID/Investigator# 160
• United States
  • Arizona
    • Phoenix, Arizona, United States, 85013
      • Site Reference ID/Investigator# 107
    • Sun City, Arizona, United States, 85351
      • Site Reference ID/Investigator# 163
  • Arkansas
    • Little Rock, Arkansas, United States, 72205
      • Site Reference ID/Investigator# 156
  • California
    • Irvine, California, United States, 92618
      • Site Reference ID/Investigator# 154
    • Laguna Hills, California, United States, 92653
      • Site Reference ID/Investigator# 161
    • Sacramento, California, United States, 95817
      • Site Reference ID/Investigator# 84
  • Colorado
    • Boulder, Colorado, United States, 80304
      • Site Reference ID/Investigator# 119
  • Florida
    • Miami, Florida, United States, 33136
      • Site Reference ID/Investigator# 111
    • Tallahassee, Florida, United States, 32308
      • Site Reference ID/Investigator# 151
  • Georgia
    • Atlanta, Georgia, United States, 30309
      • Site Reference ID/Investigator# 108
    • Atlanta, Georgia, United States, 30327
      • Site Reference ID/Investigator# 109
  • Illinois
    • Northbrook, Illinois, United States, 60062
      • Site Reference ID/Investigator# 105
  • Indiana
    • Indianapolis, Indiana, United States, 46260
      • Site Reference ID/Investigator# 152
  • Kansas
    • Lenexa, Kansas, United States, 66214
      • Site Reference ID/Investigator# 258
  • Kentucky
    • Lexington, Kentucky, United States, 40503
      • Site Reference ID/Investigator# 261
  • Michigan
    • Detroit, Michigan, United States, 48201
      • Site Reference ID/Investigator# 116
    • Traverse City, Michigan, United States, 49684
      • Site Reference ID/Investigator# 158
  • Missouri
    • St. Louis, Missouri, United States, 63110
      • Site Reference ID/Investigator# 124
  • Nevada
    • Henderson, Nevada, United States, 89052
      • Site Reference ID/Investigator# 259
  • New Hampshire
    • Lebanon, New Hampshire, United States, 03766
      • Site Reference ID/Investigator# 153
  • New York
    • Albany, New York, United States, 12205
      • Site Reference ID/Investigator# 110
  • North Carolina
    • Charlotte, North Carolina, United States, 28207
      • Site Reference ID/Investigator# 117
  • Ohio
    • Columbus, Ohio, United States, 43210
      • Site Reference ID/Investigator# 113
    • Dayton, Ohio, United States, 45409
      • Site Reference ID/Investigator# 157
  • Pennsylvania
    • Allentown, Pennsylvania, United States, 18103
      • Site Reference ID/Investigator# 114
  • Texas
    • Houston, Texas, United States, 77030
      • Site Reference ID/Investigator# 128
  • Vermont
    • Bennington, Vermont, United States, 05201
      • Site Reference ID/Investigator# 155

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 60 years (Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

• Age between 18 and 55 years
• Diagnosis of active relapse within 12 months of screening.
• At least one relapse within 12 months of screening.
• Must be able to walk at least 65 feet with or without assistance
• Off Copaxone or interferon therapy for two months prior to screening
• Able and willing to learn to self-administer weekly injections, or have a designee who will administer study medication
• Female participants must use contraceptives while on study drug

Exclusion Criteria:

• Primary progressive multiple sclerosis (PPMS)
• Immunosuppressive therapy (such as azathioprine, methotrexate (MTX), but excluding corticosteroids) within six months of randomization. Subjects with previous treatment with cyclophosphamide, total lymphoid irradiation, mitoxantrone, cladribine, or bone marrow transplantation, regardless of duration, will be excluded from participation in this study
• Systemic corticosteroid therapy within four weeks prior to the first screening Magnetic Resonance Imaging (MRI)
• Participation in any clinical study, whether or not it involves an investigational drug within three months prior to the screening visit
• Use of any investigational drug with disease-modifying potential for the treatment of multiple sclerosis (MS) within six months of randomization (prior use of investigational agents for the symptomatic treatment of MS, e.g., 4-aminopyridine (4-AP), may be allowed following discussion with medical monitor
• Concomitant statin use in doses exceeding the manufacturers' maximum recommended daily dosages for treatment of hypercholesterolemia or as part of an MS disease-modifying protocol
• Infection or risk factors for severe infections
• Excessive immunosuppression or other factors associated with it, including human immunodeficiency virus (HIV) infection
• Severe, recurrent, or persistent infections [such as Hepatitis B or C, or borreliosis or recurrent urinary tract infection (UTI) (> 3 UTIs requiring antibiotic treatment per year) or recurrent pneumonia (> 2 pneumonias requiring antibiotic treatment per year) or infected decubitus ulcers]
• Evidence of current inactive tuberculosis (TB) infection; recent exposure to mycobacterium tuberculosis (converters to a positive purified protein derivative [PPD]). Subjects with a positive PPD or a chest X-ray suggestive of prior TB infection will be excluded
• Active tuberculosis disease
• Active chronic Lyme disease
• Active syphilis
• Any other significant infection requiring hospitalization or intravenous (IV) antibiotics in the month prior to Screening; or
• Infection requiring treatment with antibiotics in the two weeks prior to Screening.

• Any of the following risk factors for development of malignancy:

  • History of lymphoma or leukemia
  • Cutaneous squamous-cell or basal cell carcinoma (EXCEPT if treated more that two years prior to Screening with evidence of recurrence or residual disease)
  • Other malignancy (EXCEPT if treated more than five years prior to Screening without evidence of recurrence or residual disease) or
  • Disease associated with an increased risk of malignancy (such as familial polyposis).
• History of major immunologic reaction (such as serum sickness or anaphylactoid reaction) to an Immunoglobulin G (IgG) containing agent (such as intravenous (IV) gamma globulin, a fusion protein, or monoclonal antibody)
• Confounders of the assessment of neurologic response including other diseases that produce chronic neurologic manifestations (such as amyotrophic lateral sclerosis, Guillain-Barre syndrome, Lyme disease, myasthenia gravis, etc.)
• Prior exposure to anti-IL-12 antibodies
• Confounders of safety assessment, such as an unstable medical condition not related to MS (including those requiring an adjustment of treatment in the four weeks prior to Screening)
• Exacerbation of asthma requiring hospitalization in the ten years prior to Screening (subjects with asthma not requiring hospitalization should be discussed with the medical monitor prior to Screening)
• Pregnant or lactating females

• The following exclusionary laboratory values at screening or baseline:

  • Hemoglobin (Hgb) <10 g/dL in females or <12 g/dL in males;
  • White blood cell (WBC) count <3 x 109/L;
  • Platelet count <100 x 109/L
  • Serum aspartate transaminase (AST) or alanine transaminase (ALT) x 3 upper limits of normal (ULN);
  • Serum total bilirubin >/= 3 mg/dL (>/= 51 x mol/L)
  • Serum creatinine >1.6 mg/dL (> 141 x mol/L)
• Subject has a recent history of substance abuse or psychiatric illness that could preclude compliance with the protocol
• In the eight weeks prior to study drug administration, the subject has received a transfusion of any blood product, or has had 500 mL or more of blood removed by repetitive or one-time blood donation, plasmapheresis, or plasma exchange, or has lost 550 mL or more blood because of hemorrhage; or
• For any reason, subject is considered by the investigator to be an unsuitable candidate to receive ABT-874.

Study Plan

How is the study designed?

Design Details

• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Triple

Number of Arms

3

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Placebo Comparator: Placebo	Drug: Placebo
Experimental: ABT-874 200 mg weekly	Drug: ABT-874/Human monoclonal antibody against IL-12
Experimental: ABT 874 QOW	Drug: ABT-874/Human monoclonal antibody against IL-12

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Time Frame
Comparison of the cumulative number of Gd enhanced (T1 weighted) lesions during the treatment phase	24 weeks
Safety and clinical laboratory parameters	monthly
vital signs	monthly

Secondary Outcome Measures

Outcome Measure	Time Frame
Magnetic Resonance Imaging endpoints	Screening
Magnetic Resonance Imaging endpoints	Baseline (Week 0)
Magnetic Resonance Imaging endpoints	Every 4 weeks after baseline through Week 24
Magnetic Resonance Imaging endpoints	Every 12 weeks from Week 26 to Week 120
Magnetic Resonance Imaging endpoints	Early Termination

Collaborators and Investigators

• Sponsor: AbbVie (prior sponsor, Abbott)
• Investigators: Study Chair: Martin Kaul, MD, AbbVie

Publications and helpful links

General Publications

• Vollmer TL, Wynn DR, Alam MS, Valdes J. A phase 2, 24-week, randomized, placebo-controlled, double-blind study examining the efficacy and safety of an anti-interleukin-12 and -23 monoclonal antibody in patients with relapsing-remitting or secondary progressive multiple sclerosis. Mult Scler. 2011 Feb;17(2):181-91. doi: 10.1177/1352458510384496. Epub 2010 Dec 6.

Study record dates

Study Major Dates

• Study Start: April 1, 2004
• Primary Completion (Actual): November 1, 2006
• Study Completion (Actual): November 1, 2006

Study Registration Dates

• First Submitted: July 7, 2004
• First Submitted That Met QC Criteria: July 8, 2004
• First Posted (Estimate): July 9, 2004

Study Record Updates

• Last Update Posted (Estimate): January 4, 2013
• Last Update Submitted That Met QC Criteria: January 2, 2013
• Last Verified: January 1, 2013

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Pathologic Processes; Nervous System Diseases; Immune System Diseases; Demyelinating Autoimmune Diseases, CNS; Autoimmune Diseases of the Nervous System; Demyelinating Diseases; Autoimmune Diseases; Multiple Sclerosis; Sclerosis; Physiological Effects of Drugs; Immunologic Factors; Antibodies; Antibodies, Monoclonal
• Other Study ID Numbers: M03-654

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No
• product manufactured in and exported from the U.S.: No